Jiangsu gdk Biotechnology (688670) Stock Overview

Jiangsu Gdk Biological Technology Co., Ltd engages in the scientific research, production, operation, and service of human vaccines. The company offers quadrivalent influenza virus split vaccines. Its product pipeline has coverage for the prevention of principal infectious diseases, including influenza, rabies, chickenpox, herpes zoster, and pneumonia. The company was founded in 2008 and is based in Taizhou, China.